The Foreign-Trade Zones Board has received from MannKind Corporation a notification of proposed production activity for its facility within subzone 76B in Danbury, Conn. MannKind currently has authority to use this facility for the production of an inhalable insulin made by a combination of imported fumaryl diketopiperazone and domestic material active ingredients. The current request would add a finished product to the scope of authority.

Production under FTZ procedures could exempt MannKind from customs duty payments on the foreign-status components used in export production. On its domestic sales, MannKind would be able to choose the duty rate that applies to FDKP carrier/receptor powder (6.5 percent) for the foreign-status components and materials in the existing scope of authority. Customs duties also could possibly be deferred or reduced on foreign-status production equipment.

Comments on this notification are due no later than Feb. 15.

Click here to register for ST&R’s Jan. 17 webinar on FTZs and bonded warehouses.

Copyright © 2021 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.

ST&R: International Trade Law & Policy

Since 1977, we have set the standard for international trade lawyers and consultants, providing comprehensive and effective customs, import and export services to clients worldwide.

View Our Services 


Cookie Consent

We use cookies on our website. By continuing to use our website, you agree to the Privacy Policy and Terms of Use.